|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EC58
|
|
gptkbp:blackBoxWarning
|
none
|
|
gptkbp:brand
|
gptkb:Braftovi
|
|
gptkbp:CASNumber
|
gptkb:1265820-89-2
|
|
gptkbp:combines
|
gptkb:Mektovi
|
|
gptkbp:contraindication
|
hypersensitivity to encorafenib
|
|
gptkbp:developedBy
|
gptkb:Array_BioPharma
|
|
gptkbp:form
|
capsule
|
|
gptkbp:genericName
|
gptkb:encorafenib
|
|
gptkbp:hasMolecularFormula
|
C22H27ClF2N6O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Braftovi
|
|
gptkbp:indication
|
treatment of melanoma
treatment of colorectal cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
BRAF inhibitor
|
|
gptkbp:molecularWeight
|
538.94 g/mol
|
|
gptkbp:patent
|
gptkb:Pfizer
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
71238361
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
abdominal pain
fatigue
rash
arthralgia
increased liver enzymes
|
|
gptkbp:target
|
gptkb:BRAF_V600E_mutant_protein
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:bfsParent
|
gptkb:Array_BioPharma
|
|
gptkbp:bfsLayer
|
5
|